Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.

Mathvink, R J; Tolman, J S; Chitty, D; Candelore, M R; Cascieri, M A; Colwell, L F; Deng, L; Feeney, W P; Forrest, M J; Hom, G J; MacIntyre, D E; Miller, R R; Stearns, R A; Tota, L; Wyvratt, M J; Fisher, M H; Weber, A E

Mathvink, R J; Tolman, J S; Chitty, D; Candelore, M R; Cascieri, M A; Colwell, L F; Deng, L; Feeney, W P; Forrest, M J; Hom, G J; MacIntyre, D E; Miller, R R; Stearns, R A; Tota, L; Wyvratt, M J; Fisher, M H; Weber, A E.

Affiliation

Mathvink RJ; Merck Research Laboratories, Rahway, New Jersey 07065, USA. robert_mathvink@merck.com

J Med Chem ; 43(21): 3832-6, 2000 Oct 19.

Article in En | MEDLINE | ID: mdl-11052788

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / Thiazoles / Adrenergic beta-Agonists / Adrenergic beta-3 Receptor Agonists Limits: Animals / Humans / Male Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2000 Document type: Article Affiliation country:

Search on Google

Add to My VHL

XML

PubMed Links